PMS24 LOWER HIP FRACTURE RATES IN THE FIRST YEAR OF THERAPY TRANSLATE INTO FAVORABLE COST-EFFECTIVENESS FOR RISEDRONATE VS. GENERIC ALENDRONATE AMONG HIGH RISK PATIENTS
May 1, 2009, 00:00 AM
10.1016/S1098-3015(10)73400-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)73400-8/fulltext
Section Title :
Section Order :
832
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73400-8&doi=10.1016/S1098-3015(10)73400-8